$ELAN
Elanco Animal Health Inc Stock $elan

$elan Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-Q Financial Statement

#000173910419000010 Filed on May 14, 2019

Income Statement

Concept	2019 Q1	2018 Q1
Revenue	$731.1M	$736.2M
YoY Change	-0.69%	4.46%
Cost Of Revenue	$343.8M	$360.0M
YoY Change	-4.5%	6.32%
Gross Profit	$387.3M	$376.2M
YoY Change	2.95%	2.73%
Gross Profit Margin	52.97%	51.1%
Selling, General & Admin	$181.1M	$180.0M
YoY Change	0.61%
% of Gross Profit	46.76%	47.85%
Research & Development	$64.10M	$65.20M
YoY Change	-1.69%
% of Gross Profit	16.55%	17.33%
Depreciation & Amortization	$75.20M	$74.30M
YoY Change	1.21%
% of Gross Profit	19.42%	19.75%
Operating Expenses	$245.2M	$245.2M
YoY Change	0.0%	-5.07%
Operating Profit	$142.1M	$131.0M
YoY Change	8.47%	21.41%
Interest Expense	$20.80M	$0.00
YoY Change
% of Operating Profit	14.64%	0.0%
Other Income/Expense, Net	-$2.600M	-$1.900M
YoY Change	36.84%
Pretax Income	$44.80M	$77.50M
YoY Change	-42.19%	-246.5%
Income Tax	$13.30M	$4.800M
% Of Pretax Income	29.69%	6.19%
Net Earnings	$31.50M	$72.70M
YoY Change	-56.67%	-173.96%
Net Earnings / Revenue	4.31%	9.88%
Basic Earnings Per Share	$0.09	$0.25
Diluted Earnings Per Share	$0.09	$0.25
COMMON SHARES
Basic Shares Outstanding	365.7M shares	293.3M shares
Diluted Shares Outstanding	366.0M shares	293.3M shares

Balance Sheet

Concept	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$272.0M
YoY Change
Cash & Equivalents	$272.1M	$263.4M
Short-Term Investments
Other Short-Term Assets	$144.0M
YoY Change
Inventory	$1.036B
Prepaid Expenses
Receivables	$684.1M
Other Receivables	$107.8M
Total Short-Term Assets	$2.278B
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$930.2M
YoY Change
Goodwill	$2.933B
YoY Change
Intangibles	$2.387B
YoY Change
Long-Term Investments	$15.70M
YoY Change
Other Assets	$219.3M
YoY Change
Total Long-Term Assets	$6.469B
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$2.278B
Total Long-Term Assets	$6.469B
Total Assets	$8.747B
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$252.1M
YoY Change
Accrued Expenses	$86.00M
YoY Change
Deferred Revenue	$171.7M
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due	$29.00M
YoY Change
Total Short-Term Liabilities	$708.2M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$2.437B
YoY Change
Other Long-Term Liabilities	$168.4M
YoY Change
Total Long-Term Liabilities	$2.605B
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$708.2M
Total Long-Term Liabilities	$2.605B
Total Liabilities	$3.551B
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	$47.90M
YoY Change
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.196B	$7.902B
YoY Change
Total Liabilities & Shareholders Equity	$8.747B
YoY Change

Cashflow Statement

Concept	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	$31.50M	$72.70M
YoY Change	-56.67%	-173.96%
Depreciation, Depletion And Amortization	$75.20M	$74.30M
YoY Change	1.21%
Cash From Operating Activities	$8.100M	$47.00M
YoY Change	-82.77%
INVESTING ACTIVITIES
Capital Expenditures	$28.00M	$32.70M
YoY Change	-14.37%
Acquisitions
YoY Change
Other Investing Activities	$500.0K	$1.700M
YoY Change	-70.59%
Cash From Investing Activities	-$31.00M	-$34.40M
YoY Change	-9.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$339.5M	-$76.50M
YoY Change	343.79%
NET CHANGE
Cash From Operating Activities	$8.100M	$47.00M
Cash From Investing Activities	-$31.00M	-$34.40M
Cash From Financing Activities	-$339.5M	-$76.50M
Net Change In Cash	-$376.9M	-$60.00M
YoY Change	528.17%
FREE CASH FLOW
Cash From Operating Activities	$8.100M	$47.00M
Capital Expenditures	$28.00M	$32.70M
Free Cash Flow	-$19.90M	$14.30M
YoY Change	-239.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	us-gaap	Business Exit Costs1 BusinessExitCosts1	0	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	263400000	USD
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001739104
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	365707234	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Elanco Animal Health Inc.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q1	elan	Asset Impairment Charges Including Inventory Write Down AssetImpairmentChargesIncludingInventoryWriteDown	0	USD
CY2019Q1	elan	Asset Impairment Charges Including Inventory Write Down AssetImpairmentChargesIncludingInventoryWriteDown	4000000	USD
CY2018Q1	elan	Contract With Customer Liability Increase From Cash Receipts ContractWithCustomerLiabilityIncreaseFromCashReceipts	68200000	USD
CY2019Q1	elan	Contract With Customer Liability Increase From Cash Receipts ContractWithCustomerLiabilityIncreaseFromCashReceipts	64200000	USD
CY2019Q1	elan	Contract With Customer Rebate Period ContractWithCustomerRebatePeriod	P6M
CY2019Q1	elan	Number Of Brands In Entitys Portfolio NumberOfBrandsInEntitysPortfolio	125	brand
CY2018Q1	elan	Payments Of Separation Related Costs Financing Activities PaymentsOfSeparationRelatedCostsFinancingActivities	0	USD
CY2019Q1	elan	Payments Of Separation Related Costs Financing Activities PaymentsOfSeparationRelatedCostsFinancingActivities	175100000	USD
CY2018Q1	elan	Proceeds From Payments To Transactions With Parent ProceedsFromPaymentsToTransactionsWithParent	-76100000	USD
CY2019Q1	elan	Proceeds From Payments To Transactions With Parent ProceedsFromPaymentsToTransactionsWithParent	-156400000	USD
CY2018Q1	elan	Restructuring Settlement And Impairment Provisions Excluding Noncash RestructuringSettlementAndImpairmentProvisionsExcludingNoncash	2400000	USD
CY2019Q1	elan	Restructuring Settlement And Impairment Provisions Excluding Noncash RestructuringSettlementAndImpairmentProvisionsExcludingNoncash	20900000	USD
CY2018Q1	elan	Restructuring Settlement And Impairment Provisions Noncash RestructuringSettlementAndImpairmentProvisionsNoncash	0	USD
CY2019Q1	elan	Restructuring Settlement And Impairment Provisions Noncash RestructuringSettlementAndImpairmentProvisionsNoncash	4000000	USD
CY2019Q1	elan	Stockholders Equity Capital Distributions Contributions From Parent StockholdersEquityCapitalDistributionsContributionsFromParent	7000000	USD
CY2018Q1	elan	Stockholders Equity Transfers To From Parent StockholdersEquityTransfersToFromParent	-69200000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	205200000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	252100000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	263400000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	677500000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	300600000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-60000000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-376900000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	651800000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	684100000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	878600000	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	909300000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-222200000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-250400000	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200000	shares
CY2018Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4000000	USD
CY2018Q4	us-gaap	Assets Assets	8956700000	USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2019Q1	us-gaap	Assets Assets	8747400000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	2504900000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	2278300000	USD
CY2018Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	2800000	USD
CY2019Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	20400000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5403300000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5398700000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2400000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	8400000	USD
CY2019Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	8300000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49200000	USD
CY2018Q1	us-gaap	Business Exit Costs1 BusinessExitCosts1	-500000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	474800000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272100000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	323400000	USD
CY2018Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	268700000	USD
CY2019Q1	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	365643911	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	365702757	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	365643911	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	365702757	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	191300000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3300000	USD
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	114800000	USD
CY2018Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	91100000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	118500000	USD
CY2019Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	120000000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	169900000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	171700000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	44500000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	65700000	USD
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	360000000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	343800000	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	658700000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	686300000	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-300000	USD
CY2018Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	20700000	USD
CY2019Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	19700000	USD
CY2018Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2400000	USD
CY2019Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	16300000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	114600000	USD
CY2019Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	131800000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74300000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	83100000	USD
CY2018Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0	USD
CY2019Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	35500000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-14500000	USD
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3900000	USD
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.062
CY2019Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.297
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	98900000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	64200000	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	15300000	USD
CY2019Q1	us-gaap	Equity Method Investments EquityMethodInvestments	15700000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	2958000000	USD
CY2019Q1	us-gaap	Goodwill Goodwill	2933100000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	77500000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	44800000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4800000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13300000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	105900000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	127600000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2453000000	USD
CY2019Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2386500000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	20800000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	400700000	USD
CY2019Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	415500000	USD
CY2018Q4	us-gaap	Inventory Gross InventoryGross	1051500000	USD
CY2019Q1	us-gaap	Inventory Gross InventoryGross	1079700000	USD
CY2018Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	47400000	USD
CY2019Q1	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	44200000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	1004100000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	1035500000	USD
CY2018Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	80400000	USD
CY2019Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	83700000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	570400000	USD
CY2019Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	580500000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	90800000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	16700000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7700000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	9500000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12700000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	19600000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	24600000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9600000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	3759200000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	3551200000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8956700000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8747400000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	970700000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	708200000	USD
CY2018Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	57600000	USD
CY2019Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	107800000	USD
CY2018Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1700000	USD
CY2019Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	500000	USD
CY2018Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	20300000	USD
CY2018Q4	us-gaap	Litigation Reserve LitigationReserve	0	USD
CY2019Q1	us-gaap	Litigation Reserve LitigationReserve	0	USD
CY2018Q4	us-gaap	Long Term Debt LongTermDebt	2472300000	USD
CY2019Q1	us-gaap	Long Term Debt LongTermDebt	2465600000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	29000000	USD
CY2019Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	29000000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2443300000	USD
CY2019Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2436600000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-76500000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-339500000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34400000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28500000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	47000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5600000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	72700000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	31500000	USD
CY2018Q4	us-gaap	Noncurrent Assets NoncurrentAssets	985900000	USD
CY2019Q1	us-gaap	Noncurrent Assets NoncurrentAssets	1006900000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1900000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2600000	USD
CY2019Q1	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	90	country
CY2019Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	5700000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	81200000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21800000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	59400000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	6600000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	80700000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.042
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	118400000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	219300000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	119200000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-30200000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	118600000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-28200000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	600000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-2000000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	199000000	USD
CY2019Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	191200000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	121500000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	168400000	USD
CY2018Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1400000	USD
CY2019Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-9400000	USD
CY2019Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	7600000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32700000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000000	USD
CY2018Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	109100000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	366000000	shares
CY2019Q1	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	106200000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113900000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	114800000	USD
CY2018Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-400000	USD
CY2019Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-500000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	922400000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	930200000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2019Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	7500000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65200000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64100000	USD
CY2018Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	202700000	USD
CY2019Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	28500000	USD
CY2018Q1	us-gaap	Restructuring Charges RestructuringCharges	100000	USD
CY2019Q1	us-gaap	Restructuring Charges RestructuringCharges	500000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	78000000	USD
CY2018Q1	us-gaap	Restructuring Reserve RestructuringReserve	57600000	USD
CY2018Q4	us-gaap	Restructuring Reserve RestructuringReserve	44400000	USD
CY2019Q1	us-gaap	Restructuring Reserve RestructuringReserve	37300000	USD
CY2018Q1	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-200000	USD
CY2018Q1	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	2400000	USD
CY2019Q1	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	24900000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	16400000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	47900000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	736200000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	731100000	USD
CY2019Q1	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 100 days from date of shipment.
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	100000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	180000000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	181100000	USD
CY2018Q1	us-gaap	Severance Costs1 SeveranceCosts1	100000	USD
CY2019Q1	us-gaap	Severance Costs1 SeveranceCosts1	500000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6900000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7700000	USD
CY2019Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	200000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	7780300000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	7902100000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	5197500000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	5196200000	USD
CY2018Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	2932900
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	500000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	293300000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	293300000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	365700000	shares
CY2019Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Note 2. Basis of Presentation</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have prepared the accompanying unaudited condensed consolidated and combined financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our combined financial statements and accompanying notes for the year ended December 31, 2018 included in our Annual Report on Form 10-K filed with the SEC on February 20, 2019.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For the periods after Separation, the financial statements are prepared on a consolidated basis and reflect the results of operations, comprehensive income, financial position, equity and cash flows resulting from our operations as an independent company. For periods prior to the Separation, our financial statements are combined, have been prepared on a standalone basis, and are derived from Lilly's consolidated financial statements and accounting records. The consolidated and combined financial statements reflect the financial position, results of operations and cash flows related to the animal health businesses that were transferred to Elanco Parent and are prepared in conformity with GAAP.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The combined financial statements include the attribution of certain assets and liabilities that historically have been held at the Lilly corporate level but which are specifically identifiable or attributable to the businesses that have been transferred to Elanco Parent. All intercompany transactions and accounts within Elanco have been eliminated. All transactions between us and Lilly are considered to be effectively settled in the combined financial statements at the time the intercompany transaction is recorded. The total net effect of the settlement of these intercompany transactions is reflected in the combined statements of cash flows as a financing activity and in the condensed consolidated and combined statement of equity as net parent company investment.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to Separation, these combined financial statements include an allocation of expenses related to certain Lilly corporate functions, including executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, prior to IPO. These expenses have been allocated to us based on direct usage or benefit where specifically identifiable, with the remainder allocated primarily on a pro rata basis of revenue, headcount and other measures. We consider the expenses methodology and results to be reasonable for all periods presented. However, the allocations may not be indicative of the actual expense that would have been incurred had we operated as an independent, publicly traded company for the periods presented. It is impractical to estimate what the standalone costs of Elanco would have been in the historical periods. After the Separation, a Transitional Services Agreement (TSA) between Lilly and Elanco went into effect. Under the terms of the TSA, we will be able to use these Lilly services for a fixed term established on a service-by-service basis. We are paying Lilly mutually agreed upon fees for the Lilly services provided under the TSA. Our consolidated and combined financial statements reflect the charges for Lilly services after the IPO. See Note 15 for additional details.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The income tax amounts in the combined financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the United States (U.S.) federal jurisdiction and various state, local and non-U.S. jurisdictions. Certain of these income tax returns are filed on a consolidated or combined basis with Eli Lilly and Company and/or its subsidiaries.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to Separation, Lilly maintained various benefit and combined stock-based compensation plans at a corporate level and other benefit plans at a country level. Our employees participated in such programs and the portion of the cost of those plans related to our employees is included in our financial statements. However, the condensed balance sheets do not include any equity issued related to stock-based compensation plans or any net benefit plan obligations unless the benefit plan covers only our dedicated employees or where the legal obligation associated with the benefit plan transferred to Elanco. Upon Lilly's full divestiture of Elanco in March 2019, all Lilly share-based awards held by our employees were converted into awards that will be settled in Elanco shares.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior to Separation, the equity balance in the combined financial statements represents the excess of total assets over liabilities, including intercompany balances between Elanco and Lilly (net parent company investment) and accumulated other comprehensive income/(loss). Net parent company investment is primarily impacted by contributions from Lilly which are the result of treasury activities and net funding provided by or distributed to Lilly. See Note 15 for further information.</font></div></div>
CY2019Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain reclassifications have been made to prior periods in the unaudited condensed consolidated and combined financial statements and accompanying notes to conform with current presentation.</font></div></div>

Files In Submission

Name	View Source	Status
0001739104-19-000010-index-headers.html	Edgar Link	pending
0001739104-19-000010-index.html	Edgar Link	pending
0001739104-19-000010.txt	Edgar Link	pending
0001739104-19-000010-xbrl.zip	Edgar Link	pending
elan-20190331.xml	Edgar Link	completed
elan-20190331.xsd	Edgar Link	pending
elan-20190331_cal.xml	Edgar Link	unprocessable
elan-20190331_def.xml	Edgar Link	unprocessable
elan-20190331_lab.xml	Edgar Link	unprocessable
elan-20190331_pre.xml	Edgar Link	unprocessable
elanco-20190331document10q.htm	Edgar Link	pending
elanco-20190331exhibit101.htm	Edgar Link	pending
elanco-20190331exhibit102.htm	Edgar Link	pending
elanco-20190331exhibit103.htm	Edgar Link	pending
elanco-20190331exhibit104.htm	Edgar Link	pending
elanco-20190331exhibit311x.htm	Edgar Link	pending
elanco-20190331exhibit312x.htm	Edgar Link	pending
elanco-20190331exhibit32xs.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
signature2.jpg	Edgar Link	pending
signaturea01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELAN
Elanco Animal Health Inc Stock $elan

2019 Q1 Form 10-Q Financial Statement

#000173910419000010 Filed on May 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELAN Elanco Animal Health Inc Stock $elan

2019 Q1 Form 10-Q Financial Statement

#000173910419000010 Filed on May 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELAN
Elanco Animal Health Inc Stock $elan